ClinicalTrials.gg
Not yet recruitingNCT07855900Updated Oct 27, 2026

SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

A Phase 3 interventional study of Survodutide in Obesity, sponsored by Boehringer Ingelheim. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Updated Oct 27, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
350
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing survodutide in Obesity — 4 open to participants now, 7 under way, 3 of them phase 3. survodutide · Obesity.

Planned enrollment
7th of 22
350 · median 121
Started
2026
with 5 others
Phase 3
9 of 22
3 open now
Registered
21st of 22
by date
Lead sponsor
22 of 22
Boehringer Ingelheim

Among the 22 studies testing survodutide in Obesity, this one is the 7th largest by planned enrollment, is one of 6 that started in 2026, is one of 9 in phase 3, and was the 21st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 22 studies testing survodutide in Obesity are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About survodutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing survodutide in Obesity, or all of them as a file.
02

Study summary

This study is open to adults with overweight or obesity. People can join the study if they have a body mass index (BMI) of 30 kg/m² or more, or a BMI of 27 kg/m² or more with at least one weight- related health problem. Participants must not have diabetes, and they must have tried to lose weight by dieting at least once in the past without success. The purpose of this study is to find out whether a medicine called survodutide helps people with overweight or obesity lose weight.

This study has 2 groups. The groups differ based on their starting dose and whether they have used similar weight-loss medicines before. Participants are put into one of the 2 groups, but everyone in the study receives the study medicine, survodutide. Participants take the medicine as an injection under the skin once a week. The dose of the medicine is slowly increased over time and then kept at a steady level. If a participant has side effects, such as stomach problems, the study doctor can adjust their dose.

Participants are in the study for about 1 year and 2 months. During this time, they visit the study site about 12 times. The study staff will also contact the participants by phone or video call for extra check-ins. The participants fill in questionnaires about their physical abilities, social activities, and how their weight affects their daily and emotional life. During the study, doctors regularly measure body weight to see whether the treatment works. They also check waist size, blood pressure, and take blood and urine samples. The doctors also regularly check participants' health and take note of any unwanted effects.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age ≥18 years at the time of signing , and at least the legal age of consent in countries where it is >18 years
  2. History of at least one self-reported unsuccessful dietary effort to lose body weight
  3. Signed and dated written informed consent in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial. Persons must be capable of giving informed consent independently
  4. Women of (WOCBP) must be ready and able to use highly effective methods of as provided in the protocol Further inclusion criteria apply.

Exclusion criteria

Exclusion criteria:

  1. Body weight change (self-reported) >2.5% during run-in period before screening
  2. Have obesity induced by other endocrinologic disorders (i.e. Cushing Syndrome) or diagnosed monogenetic or syndromic forms of obesity (i.e. melanocortin 4 receptor deficiency, leptin deficiency, or Prader Willi Syndrome)
  3. (HbA1c) ≥6.5% (≥48 mmol/mol) as measured by the central laboratory at screening
  4. History of Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM) or treatment with glucose-lowering agent (for the purpose of treating diabetes) started within 3 months before the screening visit up to and including the baseline visit Further exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
350 participants (estimated)

Study arms

  • Experimental
    SWITCH cohort

    Participants switching to survodutide

    Combination Product: Survodutide

  • Experimental
    INITIATION cohort

    Naive participants

    Combination Product: Survodutide

Interventions

  • Combination productSurvodutide

    Survodutide

    Also known as: BI 456906

06

What researchers measure

Primary outcomes

  1. Percent change in body weight from baseline to Week 52

    Time frame: At baseline and Week 52

Secondary outcomes

  1. Absolute change from baseline in PROMIS Physical Function (PF-SF10a) score (units on a scale) to Week 52

    Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) measure assesses self-reported capability in performing a range of physical activities. It evaluates perceived functioning of the upper extremities, lower extremities (mobility), and central body regions (neck, back), as well as activities of daily living. The 24-item PROMIS PF yields a total score reflecting physical function.

    Time frame: At baseline and Week 52

  2. Absolute change from baseline in PROMIS Ability to Participate in Social Roles and Activities SF8a total score (units on a scale) to Week 52

    The PROMIS Ability to Participate in Social Roles and Activities measure assesses perceived ability to perform usual social, family, leisure, and work roles. Items address limitations in engaging in routine activities, and responses are reverse-scored so that higher scores reflect better ability and fewer limitations. The 35-item measure generates a single Ability-to-Participate score.

    Time frame: At baseline and Week 52

  3. Absolute change from baseline in IWQOL-Lite-CT total scale score (units on a scale) to Week 52

    The Impact of Weight on Quality of Life-Lite Clinical Trial (IWQOL-Lite CT) consists of 20 items, assessing 3 domains of obesity related quality of life: physical, physical function, and psychosocial. Individual composite scale scores and a total score can be computed and are presented on a scale of 0 to 100, with higher scores indicating better function.

    Time frame: At baseline and Week 52

  4. Absolute change from baseline in IWQOL-Lite-CT physical scale score (units on a scale) to Week 52

    The Impact of Weight on Quality of Life-Lite Clinical Trial (IWQOL-Lite CT) consists of 20 items, assessing 3 domains of obesity related quality of life: physical, physical function, and psychosocial. Individual composite scale scores and a total score can be computed and are presented on a scale of 0 to 100, with higher scores indicating better function.

    Time frame: At baseline and Week 52

  5. Absolute change from baseline in IWQOL-Lite-CT physical function scale score (units on a scale) to Week 52

    The Impact of Weight on Quality of Life-Lite Clinical Trial (IWQOL-Lite CT) consists of 20 items, assessing 3 domains of obesity related quality of life: physical, physical function, and psychosocial. Individual composite scale scores and a total score can be computed and are presented on a scale of 0 to 100, with higher scores indicating better function.

    Time frame: At baseline and Week 52

  6. Absolute change from baseline in IWQOL-Lite-CT psychosocial scale score (units on a scale) to Week 52

    The Impact of Weight on Quality of Life-Lite Clinical Trial (IWQOL-Lite CT) consists of 20 items, assessing 3 domains of obesity related quality of life: physical, physical function, and psychosocial. Individual composite scale scores and a total score can be computed and are presented on a scale of 0 to 100, with higher scores indicating better function.

    Time frame: At baseline and Week 52

  7. Absolute change from baseline to Week 52 in Body Mass Index (BMI) [kg/m2]

    Time frame: At baseline and Week 52

  8. Absolute change from baseline to Week 52 in Waist circumference [cm]

    Time frame: At baseline and Week 52

  9. Absolute change from baseline to Week 52 in Systolic Blood Pressure (SBP) [mmHg]

    Three measurements will be captured at each scheduled assessment time point. The mean of these 3 measurements \[or the mean of the available measurements if fewer\] will be calculated and used in the endpoint definition.

    Time frame: At baseline and Week 52

  10. Absolute change from baseline to Week 52 in Glycosylated Haemoglobin A1c (HbA1c) [%]

    Time frame: At baseline and Week 52

  11. Relative change from baseline to Week 52 in High Sensitivity C-Reactive Protein (hs-CRP) [mg/L]

    Time frame: At baseline and Week 52

  12. Relative change from baseline to Week 52 in Non-High-Density Lipoprotein (HDL) cholesterol [mg/dL]

    Time frame: At baseline and Week 52

  13. Relative change from baseline to Week 52 in Triglycerides [mg/dL]

    Time frame: At baseline and Week 52

07

Study locations

2 sites
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2029, 35 months later.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 35 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Jun 2028 → Nov 2029 and completion Jun 2028 → Nov 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 2, 2026
StartEst.
Nov 7, 2026
Primary completionEst.
Nov 6, 2029was Jun 2028
CompletionEst.
Nov 6, 2029was Jun 2028
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • The Jones Center Clinical Research, LLC · Macon, United States
Oct 27, 2026
Primary completion
Jun 25, 2028→Nov 6, 2029
Oct 27, 2026
Study completion
Jun 25, 2028→Nov 6, 2029
Oct 27, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 2 updates
  1. Oct 27, 2026
    1 site added
    Show site
    • The Jones Center Clinical Research, LLC · Macon, United States
    Primary completion Jun 25, 2028→Nov 6, 2029
    Study completion Jun 25, 2028→Nov 6, 2029
    + 1 other change: verification date
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855900
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Nov 7, 2026 (estimated)
Primary completion
Nov 6, 2029 (estimated)
Completion
Nov 6, 2029 (estimated)
Last update
Oct 27, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
1-800-243-0127

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Survodutide

Start the discussion